Retatrutide: The Triple-Agonist Peptide Explained
Retatrutide targets three metabolic receptors at once — GLP-1, GIP and glucagon. A research overview of why the triple-agonist approach is drawing so much attention.
What is Retatrutide?
Retatrutide is an investigational peptide that acts on three receptors simultaneously: GLP-1, GIP, and the glucagon receptor. It is sometimes described as a triple agonist, and it represents one of the most studied directions in current metabolic research.
Why Three Receptors?
Earlier compounds targeted one or two of these pathways. Retatrutide adds glucagon-receptor activity to the mix.
GLP-1 and GIP are studied for appetite signalling, insulin response, and gastric emptying.
Glucagon-receptor activation is of particular interest because it has been studied for its role in energy expenditure and fat metabolism — potentially complementing the appetite-side effects of the other two pathways.
What the Research Has Explored
- Body-weight reduction in clinical trials across escalating doses
- Energy expenditure and fat-oxidation pathways
- Appetite regulation
- Broader metabolic markers
Where It Sits Among GLP-1 Peptides
If semaglutide is single-pathway and tirzepatide is dual-pathway, retatrutide is the triple-pathway option. The trade-offs between them are exactly what researchers are working to characterise — our retatrutide vs tirzepatide vs semaglutide comparison breaks this down side by side.
Availability at Peptides & You
Retatrutide is available at Peptides & You as a lab-tested lyophilised vial with a Janoshik Certificate of Analysis. Review the verified result at peptidesandyou.com/lab-results or view the product at peptidesandyou.com/product/retatrutide.
For laboratory and research use only. Not for human or veterinary consumption. These statements have not been evaluated by the U.S. FDA or the Philippine FDA.